Company Jiangsu Gdk Biological Technology Co., Ltd

688670

CNE100004NR4

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals

JIANGSU GDK BIOLOGICAL TECHNOLOGY CO., LTD

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 29/04/2024 BST			5-day change	1st Jan Change
17.5 ^CNY	-0.34%		+3.49%	-38.51%

04-15	Jiangsu Gdk Biological Technology Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
2023	Jiangsu Gdk Biological Technology Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	CI

Jiangsu gdk Biotechnology Co Ltd is a biopharmaceutical company engaged in the research, development, production, and sales of human vaccines. The Companyâs main product is a tetravalent influenza virus split vaccine, which is mainly used to prevent influenza caused by two influenza A virus strains and two influenza B virus strains. The Company's research products also include a variety of human vaccines for the prevention of epidemic colds, rabies, chickenpox, shingles, and pneumonia. The Company distributes its service within the domestic market.

Number of employees: 451

CNY in Million	2022	Weight	2023	Weight	Delta
Quadrivalent Influenza Virus Split Vaccine 100.0 %	318	100.0 %	135	100.0 %	-57.74%

CNY in Million	2022	Weight	2023	Weight	Delta
China 100.0 %	318	100.0 %	135	100.0 %	-57.74%

Managers	Title	Age	Since
Jian Hui Zhang CEO	Chief Executive Officer	66	26/10/23
Qiang Huang DFI	Director of Finance/CFO	44	31/03/21
Jun Yu CHM	Chairman	55	31/05/15
Jian Guo Xia BRD	Director/Board Member	51	31/05/15
Hua Hai Tan IRC	Investor Relations Contact	44	09/05/23

Members of the board	Title	Age	Since
Rong Shao BRD	Director/Board Member	62	14/06/20
Liang Bin Zhang BRD	Director/Board Member	49	31/05/15
Jian Qiang Guan BRD	Director/Board Member	62	14/06/20
Shen Qian Nie BRD	Director/Board Member	75	31/05/15
Jun Yu CHM	Chairman	55	31/05/15
Jian Guo Xia BRD	Director/Board Member	51	31/05/15
Da Chang Wei CHM	Chairman	55	14/06/20
Ling Huang BRD	Director/Board Member	58	14/06/20
Hui Sheng Yu BRD	Director/Board Member	28	31/01/17

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	123,200,000	27,807,066 ( 22.57 %)	0	22.57 %

Name	Equities	%	Valuation
Huatai-PineBridge Fund Management Co., Ltd. 0.9848 %	422,496	0.9848 %	1 M ¥
China Asset Management Co., Ltd. 0.8283 %	355,352	0.8283 %	923 848 ¥
Zhong Ou Asset Management Co., Ltd 0.4292 %	184,160	0.4292 %	478 781 ¥
China Merchants Fund Management Co., Ltd. 0.3455 %	148,221	0.3455 %	385 346 ¥
UBS SDIC Fund Management Co., Ltd. 0.2789 %	119,670	0.2789 %	311 119 ¥
Wanjia Asset Management Co., Ltd. 0.2070 %	88,800	0.2070 %	230 863 ¥
Hotland Innovation Asset Management Co. Ltd. 0.1769 %	75,878	0.1769 %	197 268 ¥
Minsheng Royal Fund Management Co., Ltd. 0.1268 %	54,405	0.1268 %	141 443 ¥
China Southern Asset Management Co., Ltd. 0.0460 %	19,723	0.0460 %	51 276 ¥
Lion Fund Management Co., Ltd. 0.0329 %	14,127	0.0329 %	36 728 ¥

Name	Equities	%	Valuation
Shen Qian Nie 5.777 %	3,550,219	5.777 %	9 M ¥
Jian Guo Xia 3.566 %	2,191,209	3.566 %	6 M ¥

Jiangsu gdk Biotechnology Co., Ltd.

12 Yujin Road

225300, Taizhou

http://www.gdkbio.com

address Jiangsu Gdk Biological Technology Co., Ltd(688670)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

17.5

Average target price

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals

	1st Jan change	Capi.
JIANGSU GDK BIOLOGICAL TECHNOLOGY CO., LTD	-38.51%	298M
CSL LIMITED	-3.79%	88.14B
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.51B
BIOGEN INC.	-15.94%	31.67B
UCB	+52.66%	24.62B
BIOMARIN PHARMACEUTICAL INC.	-14.50%	15.65B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.97B
INCYTE CORPORATION	-14.38%	12.07B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.81B

Biopharmaceuticals